Publications in collaboration with researchers from Complexo Hospitalario Universitario de Ferrol (16)

2020

  1. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

  2. Rapid expansion of a HIV-1 subtype f cluster of recent origin among men who have sex with men in Galicia Spain

    Journal of Acquired Immune Deficiency Syndromes

2010

  1. Artificial intelligence techniques for colorectal cancer drug metabolism: Ontologies and complex networks

    Current Drug Metabolism, Vol. 11, Núm. 4, pp. 347-368

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

    Medicina Clinica, Vol. 129, Núm. 10, pp. 361-365

2006

  1. "Liver toxicity and metabolic alterations associated with nevirapine therapy and the influence of hepatitis C virus infection"

    Nutrition and Metabolic Disorders in HIV Infection, Vol. 5, Núm. 1, pp. 891-897

  2. Actividad asistencial en las consultas externas de las unidades de reumatología de Galicia

    Reumatologia Clinica, Vol. 2, Núm. 5, pp. 239-246

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

  2. Anticentromere antibodies and lung disease without skin involvement

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 14, Núm. 4, pp. 196-198

  3. Multicenter randomized, controlled study of intramuscular administration of interferon-β for the treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 1, pp. 27-30

  4. Tolerance and efficacy of subcutaneous interferon-β administered for treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 2, pp. 65-67